CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 96 filers reported holding CONCERT PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 0.19 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $375,000 | -3.8% | 31,092 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $390,000 | -0.8% | 31,092 | +17.4% | 0.00% | – |
| Q3 2018 | $393,000 | -11.9% | 26,492 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $446,000 | -26.5% | 26,492 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $607,000 | -15.6% | 26,492 | -4.7% | 0.00% | 0.0% |
| Q4 2017 | $719,000 | +75.4% | 27,792 | 0.0% | 0.00% | – |
| Q3 2017 | $410,000 | +5.7% | 27,792 | 0.0% | 0.00% | – |
| Q2 2017 | $388,000 | -18.1% | 27,792 | 0.0% | 0.00% | -100.0% |
| Q1 2017 | $474,000 | +65.7% | 27,792 | 0.0% | 0.00% | – |
| Q4 2016 | $286,000 | +1.8% | 27,792 | 0.0% | 0.00% | – |
| Q3 2016 | $281,000 | -9.9% | 27,792 | 0.0% | 0.00% | -100.0% |
| Q2 2016 | $312,000 | -10.3% | 27,792 | +5.7% | 0.00% | 0.0% |
| Q1 2016 | $348,000 | +22.1% | 26,292 | +75.3% | 0.00% | 0.0% |
| Q4 2015 | $285,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 1,149,120 | $14,559,000 | 2.72% |
| Corriente Advisors, LLC | 680,000 | $8,595,000 | 2.05% |
| ACUTA CAPITAL PARTNERS, LLC | 537,500 | $6,794,000 | 1.85% |
| INGALLS & SNYDER LLC | 1,362,203 | $17,218,000 | 0.85% |
| Kensington Investment Counsel, LLC | 75,533 | $955,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 384,039 | $4,854,000 | 0.43% |
| Opaleye Management Inc. | 254,000 | $3,211,000 | 0.42% |
| RA Capital Management | 1,823,520 | $23,049,000 | 0.32% |
| Perceptive Advisors | 2,150,641 | $27,184,000 | 0.29% |
| Parkman Healthcare Partners LLC | 50,290 | $636,000 | 0.16% |